Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women
✍ Scribed by Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. García; Nubia Muñoz; Luisa L. Villa; Janine Bryan; Frank J. Taddeo; Shuang Lu; Mark T. Esser; Scott Vuocolo; Carlos Sattler; Eliav Barr
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- French
- Weight
- 103 KB
- Volume
- 122
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naïve to vaccine HPV types. A total of 6,004 female subjects aged 9–24 were recruited from Brazil, Mexico, Colombia, Costa Rica, Guatemala and Peru. Subjects were randomized to immunization with intramuscular (deltoid) injections of HPV vaccine or placebo at enrollment (day 1), month 2 and month 6. Among vaccinated subjects in the per‐protocol population from Latin America, quadrivalent HPV vaccine was 92.8 and 100% effective in preventing cervical intraepithelial neoplasia and external genital lesions related to vaccine HPV types, respectively. These data support vaccination of adolescents and young adults in the region, which is expected to greatly reduce the burden of cervical and genital cancers, precancers and genital warts. © 2007 Wiley‐Liss, Inc.